Archives
-
Two Therapeutic Targets Identified for Deadly Lung Cancer
(July 26, 2019) The vast majority of deadly lung cancer cases (85 percent) are termed non-small-cell lung carcinomas (NSCLCs), which often contain a mutated gene called LKB1. Salk Institute researchers have now discovered precisely why inactive LKB1 results in cancer development. The surprising results, published in the online version of Cancer Discovery on July 26, 2019, highlight how LBK1 communicates with two enzymes that suppress inflammation in addition to cell growth, to block tumor growth. The findings could lead to new therapies for NSCLC.
Latest Research Articles
-
Antarctic: The IceCube Neutrino Experiment is Growing
-
CBD Oil & The Endocannabinoid System
-
Underwater Glacial Melting Occurring Much Faster than Predicted
-
Finnish Company Uses NASA’s Concept to Create Food from Thin Air
-
Electricity-Driven Undersea Reactions May Have Been Important For the Emergence of Life
-
3D-Printed Pill Samples Gut Microbiome to Aid Diagnosis and Treatment
-
ICR Claims New Gene Test Could Detect Prostate Cancer Patients
-
Microrobots Show Promise for Treating Tumors
-
Cold, Dry Planets Could Have a Lot of Hurricanes
-
Eco-Friendly Home Cleaning Products
-
DNA Testing Companies: What They Can and Cannot Reveal about Your Ancestry
-
Microfluidics Device Helps Diagnose Sepsis in Minutes